Advanced | Nano Publications

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Lung

Recent clinical studies have demonstrated the efficacy of anti-PD-1 in recurrent/metastatic HNSCC and upfront metastatic NSCLC patients. However, most patients with recurrent/metastatic HNSCC demon-strate innate (primary) resistance to checkpoint inhibition and do not respond to initial therapy and only a subset of metastatic HNSCC/NSCLC patients benefits from this treatment. […]

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

Clinical Data NBTXR3, Congress Abstracts, STS

A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. […]